OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

John O. Mascarenhas, MD, professor, medicine, Icahn School of Medicine at Mount Sinai; director, Center of Excellence for Blood Cancers and Myeloid Disorders, director, Adult Leukemia Program, member, The Tisch Cancer Institute

Dr Mascarenhas on the Efficacy of Imetelstat Plus Ruxolitinib in Higher-Risk Myelofibrosis

Olivia Fankuchen, MD, MS, clinical fellow, Hematology and Oncology, New York University Langone Health

Dr Fankuchen on Practice-Informing Updates to the Thoracic Oncology Treatment Paradigm

Dr Amanam on the Real-World Efficacy of First-Line Luspatercept vs Erythropoiesis-Stimulating Agents in Lower-Risk MDS

Dr Amanam on the Real-World Efficacy of First-Line Luspatercept vs Erythropoiesis-Stimulating Agents in Lower-Risk MDS

Dr Pal on Genomic Activity With Adjuvant Atezolizumab vs Placebo in High-Risk Resected RCC

Dr Pal on Genomic Activity With Adjuvant Atezolizumab vs Placebo in High-Risk Resected RCC

Thaker

Dr Thaker on Data for IMNN-001 Plus Neoadjuvant Chemotherapy in Newly Diagnosed Ovarian Cancer

Tagawa

Dr Tagawa on the Evaluation of Lutetium Lu 177 Rospatamab Tetraxetan Plus SOC in mCRPC

Jessica Paulus, ScD

Paulus on the Rationale for Utilizing an External Control Arm in a Single-Arm HER2+ Breast Cancer Trial

Mitchell Parma, MD

Dr Parma on Survival Outcomes With Immunotherapy in Patients With NSCLC Brain Metastases

Alicia Morgans, MD, MPH of Dana-Farber Cancer Institute

Dr Morgans on HRQOL Outcomes With Darolutamide Plus ADT in mHSPC

Saghir

Dr Saghir on Ribociclib Plus Endocrine Therapy in Premenopausal HR+/HER2-Negative Advanced Breast Cancer

Alexey Danilov, MD, PhD

Dr Danilov on the Manuscript From Bridging the Gaps in Leukemia, Lymphoma, and Multiple Myeloma

Dr. Abramson is Professor of Medicine at Harvard Medical School and Director of the Center for Lymphoma at the Mass General Cancer Center.

Dr Abramson on Findings with Glofitamab, Gemcitabine and Oxaliplatin in R/R DLBCL

Niels van de Donk - Amsterdam UMC

Dr van de Donk on Initial Safety and Efficacy Findings From the First-In-Human Study of JNJ-5322 in R/R Multiple Myeloma

Paolo Ghia, MD, PhD

Dr Ghia on the Efficacy of Fixed-Duration Ibrutinib Plus Venetoclax in CLL/SLL

Kelsey Pan, MD, MPH

Dr Pan on the Real-World Utilization of Tarlatamab in Patients With SCLC

Robin Jones, MD, MRCP

Dr Jones on the Evolving Treatment Landscape in GIST

Daniel J. DeAngelo, MD, PhD, chief of the Division of Leukemia and an institute physician at Dana-Farber Cancer Institute, as well as a professor of medicine at Harvard Medical School

Dr DeAngelo on Challenges With Utilizing Pediatric-Inspired Regimens in Adult and AYA ALL

GI Cancer Experts on Notable Updates Shared During the 2025 ASCO Annual Meeting

GI Cancer Experts on Notable Updates Shared During the 2025 ASCO Annual Meeting

TARANTINO

Dr Tarantino on the Evolving Role of THP in HER2+ Metastatic Breast Cancer

ARNOLD

Dr Arnold on the Evaluation of Chemo With Amivantamab or Cetuximab in RAS/BRAF Wild-Type mCRC

Markman

Dr Markman the Significance of PROs in Patients With Locally Advanced Cervical Cancer

Christine Chung, MD

Dr Chung on the Potential Role for Ficerafusp Alfa Plus Pembrolizumab in the HPV-Negative HNSCC Paradigm

Mehta

Dr Mehta on the FDA Approval of Tafasitamab Plus Rituximab/Lenalidomide in R/R Follicular Lymphoma

Massimo Cristofanilli, MD, Weill Cornell Medical College

Dr Cristofanilli on the Next Steps With Camizestrant in HR+/HER2– Breast Cancer

C. Ola Landgren, MD, PhD

Dr Landgren on the Efficacy of Dara-KRd in Newly Diagnosed Myeloma Regardless of Transplant Eligibility

Rami Komrokji, MD, vice chair, Malignant Hematology Department, senior member, Malignant Hematology and Experimental Therapeutics Program, Moffitt Cancer Center; professor, medicine & oncologic sciences, College of Medicine, University of South Florida

Dr Komrokji on the Effect of Prior Treatment on Imetelstat Activity in Transfusion-Dependent LR-MDS

Kate Gasparini, PharmD, BCOP, BCPPS, of Memorial Sloan Kettering Cancer Center

Dr Gasparini on Challenges With Oral Therapies in Pediatric Patients or Patients With Dysphagia

Yi Lin, MD, PhD

Dr Lin on the Rationale for Evaluating Cilta-Cel–Associated Late-Onset Toxicities in Myeloma

Jessica Paulus, ScD

Paulus on Factors Contributing to Earlier Onset of CRC in Younger Patients

Linda R. Duska, MD, MPH

Dr Duska on the Adoption of Pembrolizumab Plus Concurrent CRT as a SOC in Advanced Cervical Cancer

12345678
...
479>